Table 5.
Comparison of the Endothelial Functions in the Control Group and Hypertensive Patients and Between the Groups Before and After Treatment
| Control | Hypertension | |||||
|---|---|---|---|---|---|---|
| Pre‐ASA | Post‐ASA | P | Pre‐ASA | Post‐ASA | P | |
| BA diameter | 38.6 ± 5.0 | 40.1 ± 5.0 | < 0.001 | 38.5 ± 4.9 | 39.8 ± 4.6 | < 0.001 |
| FMD diameter | 43.3 ± 4.9 | 45.4 ± 5.2 | < 0.001 | 42.2 ± 4.7 | 44.1 ± 4.4 | < 0.001 |
| FMD % | 12.4 ± 3.7 | 13.3 ± 5.0 | NS | 9.8 ± 3.0 | 11.0 ± 3.1 | 0.03 |
| NID diameter | 43.6 ± 5.0 | 46.0 ± 5.3 | < 0.001 | 42.9 ± 4.7 | 44.7 ± 4.4 | < 0.001 |
| NID % | 13.3 ± 3.3 | 13.5 ± 5.0 | NS | 11.6 ± 3.7 | 11.9 ± 3.1 | NS |
| Control | ||||||
| ASA 100 mg | ASA 300 mg | |||||
| Pre‐ASA | Post‐ASA | P | Pre‐ASA | Post‐ASA | P | |
| BA diameter | 38.0 ± 4.8 | 39.5 ± 5.0 | < 0.001 | 39.2 ± 5.3 | 40.8 ± 4.9 | < 0.001 |
| FMD diameter | 42.6 ± 4.8 | 44.5 ± 5.0 | < 0.001 | 43.9 ± 5.1 | 46.3 ± 5.2 | < 0.001 |
| FMD % | 12.4 ± 4.2 | 12.9 ± 4.9 | NS | 12.8 ± 3.2 | 13.5 ± 5.1 | NS |
| NID diameter | 42.8 ± 4.9 | 45.1 ± 5.3 | < 0.001 | 44.5 ± 5.2 | 46.9 ± 5.2 | < 0.001 |
| NID % | 12.6 ± 3.5 | 12.9 ± 4.9 | NS | 13.2 ± 3.2 | 13.7 ± 5.1 | NS |
| Hypertension | ||||||
| ASA 100 mg | ASA 300 mg | |||||
| Pre‐ASA | Post‐ASA | P | Pre‐ASA | Post‐ASA | P | |
| BA diameter | 37.9 ± 5.0 | 39.3 ± 4.6 | < 0.001 | 39.0 ± 4.8 | 40.3 ± 4.6 | 0.001 |
| FMD diameter | 41.7 ± 5.0 | 43.6 ± 4.6 | < 0.001 | 42.6 ± 4.5 | 44.6 ± 4.3 | < 0.001 |
| FMD % | 10.2 ± 2.5 | 11.1 ± 3.0 | 0.022 | 9.4 ± 3.5 | 10.9 ± 3.3 | 0.009 |
| NID diameter | 42.5 ± 4.9 | 44.2 ± 4.6 | < 0.001 | 43.3 ± 4.5 | 45.1 ± 4.3 | 0.001 |
| NID % | 11.8 ± 3.4 | 12.3 ± 3.0 | NS | 11.3 ± 4.0 | 11.6 ± 3.8 | NS |
Abbreviations: ASA, acetylsalicylic acid; BA, brachial artery; FMD, flow‐mediated dilatation; NID, nitroglycerin‐induced dilatation; NS, not significant.